Laboratory Department, Linyi Central Hospital, Yishui, Shandong, China.
Department of Clinical Pharmacy, LinYi People's Hospital, Linyi, Shandong, China.
Expert Rev Clin Pharmacol. 2022 Sep;15(9):1011-1016. doi: 10.1080/17512433.2022.2118111. Epub 2022 Aug 30.
Olanzapine (OLZ) is one of the most effective antipsychotic agents, however, its clinical utility has been limited by weight gain. Samidorphan (SAM) is a μ-opioid receptor antagonist and it can reduce the weight gain associated with OLZ. A combination of OLZ and SAM (OLZ/SAM) has been developed to provide the antipsychotic efficacy of OLZ, while mitigating OLZ-associated weight gain.
A comprehensive literature search was conducted in PubMed. Key search terms included SAM and weight gain associated with OLZ. The pharmacological action, clinical efficacy, and safety of SAM were reviewed.
OLZ can lead to weight gain. SAM is a new drug that acts as an opioid receptor antagonist that can decrease weight gain. SAM mitigates OLZ-associated weight gain while preserving the antipsychotic efficacy of OLZ. Clinical trials have confirmed that OLZ/SAM significantly improved psychotic symptoms, and resulted in significantly less weight gain than OLZ. OLZ/SAM was well tolerated. Therefore, it is a potential new treatment option for schizophrenia.
奥氮平（OLZ）是最有效的抗精神病药物之一，但由于体重增加，其临床应用受到限制。氨磺必利（SAM）是一种μ-阿片受体拮抗剂，可减少与 OLZ 相关的体重增加。OLZ 和 SAM 的组合（OLZ/SAM）已被开发出来，以提供 OLZ 的抗精神病疗效，同时减轻 OLZ 相关的体重增加。
在 PubMed 上进行了全面的文献检索。关键搜索词包括 SAM 和与 OLZ 相关的体重增加。综述了 SAM 的药理学作用、临床疗效和安全性。
OLZ 可导致体重增加。SAM 是一种新型药物，作为阿片受体拮抗剂，可减少体重增加。SAM 减轻了与 OLZ 相关的体重增加，同时保留了 OLZ 的抗精神病疗效。临床试验证实，OLZ/SAM 显著改善了精神病症状，与 OLZ 相比，体重增加明显减少。OLZ/SAM 耐受性良好。因此，它是一种治疗精神分裂症的潜在新选择。
